Venetoclax

7:04
Saad Usmani: BELLINI, CANDOR, ICARIA-MM and CAR-T
Saad Usmani
2:24
Synergy: MCL-1 & BCL-2 inhibition for myeloma
Enrique Ocio
10:19
Key game-changers in multiple myeloma
Kenneth Anderson
3:52
Venetoclax & AML
Charles Craddock
4:43
Hematological malignancy amid COVID-19
Naval Daver
2:21
Targeted therapy for MDS
Drorit Merkel
1:14
Horizon scan of MDS treatments
Alan List
0:52
Azacitidine in the treatment of MDS
David Steensma
1:32
Novel drug targets for MDS
Stephen Nimer
1:02
Update on treatments for high- and low-risk MDS
Nicolas Bonadies
1:26
New data in myelodysplastic syndromes
Valeria Santini
1:16
Novel therapeutic for AML: CYC065 combinations
Mhairi Copland
4:17
Ibrutinib-rituximab for CLL: efficacious, but challenging toxicity profile
Jacqueline Barrientos
1:34
Venetoclax with mini-hyper-CVD for ALL
Nitin Jain
2:37
Allo-HSCT for CLL in the era of novel agents
Lindsey Roeker
1:28
Encouraging results for ibrutinib with venetoclax in R/R CLL
Nitin Jain
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals